Lytic metastatic bone lesion

Summary

Lytic metastatic bone lesion (MONDO:0043731) is a disease and 9 clinical trials. Top therapeutic interventions include denosumab. A subtype of bone resorption disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lytic metastatic bone lesion
Mondo ID	MONDO:0043731
MeSH	D010014
NCIT	C35371
SNOMED CT	203522001
UMLS	C0302313
MedGen	137065
Is cancer (heuristic)	no

Also known as: lytic metastatic bone lesion · Osteolyses · osteolysis · osteolytic lesion

Disease family

This is a subtype of bone resorption disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone remodeling disease › bone resorption disease › lytic metastatic bone lesion

Related subtypes (2): osteoporosis, osteitis fibrosa

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Denosumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01272830	PHASE2	COMPLETED	Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements
NCT02299817	PHASE2	UNKNOWN	Denosumab for Treating Periprosthetic Osteolysis.
NCT04255966	Not specified	ACTIVE_NOT_RECRUITING	Plasmafit® Revision Structan® Hip Endoprosthesis Cup
NCT06824545	Not specified	NOT_YET_RECRUITING	Incidence & Clinical Significance of Osteolysis Following PEEK Suture Anchor Use in Hand & Wrist Surgery
NCT00367289	Not specified	COMPLETED	CT for Diagnosis of Implant Stability in Revision Arthroplasty
NCT01198457	Not specified	COMPLETED	Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
NCT01464645	Not specified	TERMINATED	Post-Market Study of the Modular Revision Hip System
NCT05018130	Not specified	UNKNOWN	Bio-Integrative Versus Metallic Screws for Calcaneus Osteotomies
NCT06041828	Not specified	WITHDRAWN	Regular Home-use Dual Light Photodynamic Therapy in the Prevention of Osteolysis After Dental Implant Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DENOSUMAB	4	1